Table 2.
Demographic and clinical characteristics of patients with asthma at the University of Washington Medicine during 2011-2017.
| Characteristic | Data instances (N=68,244), n (%) | Data instances connecting to asthma hospital encounters in the subsequent 12 months (n=1184), n (%) | Data instances connecting to no asthma hospital encounter in the subsequent 12 months (n=67,060), n (%) | ||||
| Age (years) | |||||||
|
|
<40 | 23,459 (34.38) | 466 (39.36) | 22,993 (34.29) | |||
|
|
40-65 | 33,889 (49.66) | 583 (49.24) | 33,306 (49.67) | |||
|
|
>65 | 10,896 (15.97) | 135 (11.40) | 10,761 (16.05) | |||
| Gender | |||||||
|
|
Male | 24,198 (35.46) | 551 (46.54) | 23,647 (35.26) | |||
|
|
Female | 44,046 (64.54) | 633 (53.46) | 43,413 (64.74) | |||
| Race | |||||||
|
|
American Indian or Alaska native | 1358 (1.99) | 32 (2.70) | 1326 (1.98) | |||
|
|
Asian | 5721 (8.38) | 96 (8.11) | 5625 (8.39) | |||
|
|
Black or African American | 8420 (12.34) | 520 (43.92) | 7900 (11.78) | |||
|
|
Native Hawaiian or other Pacific islander | 673 (0.99) | 14 (1.18) | 659 (0.98) | |||
|
|
White | 47,747 (69.97) | 507 (42.82) | 47,240 (70.44) | |||
|
|
Unknown or not reported | 4325 (6.34) | 15 (1.27) | 4310 (6.43) | |||
| Ethnicity | |||||||
|
|
Hispanic | 3526 (5.17) | 82 (6.93) | 3444 (5.14) | |||
|
|
Non-Hispanic | 56,309 (82.51) | 1062 (89.70) | 55,247 (82.38) | |||
|
|
Unknown or not reported | 8409 (12.32) | 40 (3.38) | 8369 (12.48) | |||
| Insurance | |||||||
|
|
Private | 40,009 (58.63) | 424 (35.81) | 39,585 (59.03) | |||
|
|
Public | 28,787 (42.18) | 756 (63.85) | 28,031 (41.80) | |||
|
|
Self-paid or charity | 1366 (2.00) | 65 (5.49) | 1301 (1.94) | |||
| Number of years from the first encounter related to asthma in the data set | |||||||
|
|
≤3 | 60,873 (89.20) | 986 (83.28) | 59,887 (89.30) | |||
|
|
>3 | 7371 (10.80) | 198 (16.72) | 7173 (10.70) | |||
| Asthma medication prescription | |||||||
|
|
Inhaled corticosteroid | 28,889 (42.33) | 626 (52.88) | 28,263 (42.15) | |||
|
|
Inhaled corticosteroid and long-acting β-2 agonist combination | 22,015 (32.26) | 499 (42.15) | 21,516 (32.08) | |||
|
|
Leukotriene modifier | 8171 (11.97) | 201 (16.98) | 7970 (11.88) | |||
|
|
Long-acting β-2 agonist | 12,293 (18.01) | 374 (31.59) | 11,919 (17.77) | |||
|
|
Mast cell stabilizer | 47 (0.07) | 4 (0.34) | 43 (0.06) | |||
|
|
Short-acting inhaled β-2 agonist | 47,808 (70.05) | 1010 (85.30) | 46,798 (69.79) | |||
|
|
Systemic corticosteroid | 18,699 (27.40) | 614 (51.86) | 18,085 (26.97) | |||
| Comorbidity | |||||||
|
|
Allergic rhinitis | 11,449 (16.78) | 172 (14.53) | 11,277 (16.82) | |||
|
|
Anxiety or depression | 19,885 (29.14) | 372 (31.42) | 19,513 (29.10) | |||
|
|
Bronchopulmonary dysplasia | 1 (0) | 0 (0) | 1 (0) | |||
|
|
Chronic obstructive pulmonary disease | 3826 (5.61) | 133 (11.23) | 3693 (5.51) | |||
|
|
Cystic fibrosis | 61 (0.09) | 1 (0.08) | 60 (0.09) | |||
|
|
Eczema | 3891 (5.70) | 66 (5.57) | 3825 (5.70) | |||
|
|
Gastroesophageal reflux | 12,291 (18.01) | 238 (20.10) | 12,053 (17.97) | |||
|
|
Obesity | 7845 (11.50) | 177 (14.95) | 7668 (11.43) | |||
|
|
Sinusitis | 7261 (10.64) | 89 (7.52) | 7172 (10.69) | |||
|
|
Sleep apnea | 4556 (6.68) | 88 (7.43) | 4468 (6.66) | |||
| Smoking status | |||||||
|
|
Current smoker | 14,081 (20.63) | 255 (21.54) | 13,826 (20.62) | |||
|
|
Former smoker | 15,530 (22.76) | 221 (18.67) | 15,309 (22.83) | |||
|
|
Never smoker or unknown | 38,633 (56.61) | 708 (59.80) | 37,925 (56.55) | |||